清心开窍方辅助治疗轻中度阿尔茨海默病临床研究

Clinical Study on Qingxin Kaiqiao Prescription Assisting Treatment for Mild-to-Moderate Alzheimer Disease

目的:观察清心开窍方辅助治疗轻中度阿尔茨海默病的疗效及对神经凋亡因子的影响。方法:选择90例轻中度阿尔茨海默病患者,按随机数字表法分为观察组和对照组各45例。对照组给予盐酸多奈哌齐治疗,观察组在对照组基础上给予清心开窍方治疗,连续治疗8周。比较2组临床疗效、认知功能、神经凋亡因子和不良反应发生率。结果:观察组总有效率为93.33%,高于对照组73.33%(P<0.05)。治疗前,2组蒙特利尔认知评估量表(MoCA)评分、简易智力状态检查量表(MMSE)评分比较,差异无统计学意义(P>0.05)。治疗后,观察组MoCA评分、MMSE评分高于治疗前和对照组(P<0.05)。治疗前,2组Bax、Bcl-2、半胱氨酸天门冬氨酸蛋白酶-3(Caspase-3)水平比较,差异无统计学意义(P>0.05)。治疗后,观察组Bax、Caspase-3水平低于治疗前和对照组(P<0.05),Bcl-2水平高于治疗前和对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:清心开窍方辅助治疗轻中度阿尔茨海默病效果良好,可显著改善认知功能,抑制神经细胞凋亡,且安全性良好。

Objective:To observe the curative effect of Qingxin Kaiqiao Prescription assisting treatment for mild-to-moderate Alzheimer disease and its effect on apoptosis factors.Methods:A total of 90 cases of patients with mild-to-moderate Alzheimer disease were selected and divided into the observation group and the control group according to the random number table method,with 45 cases in each group.The control group was treated with Donepezil Hydrochloride Tablets,and the observation group was additionally treated with Qingxin Kaiqiao Prescription based on the treatment of the control group.Both groups were treated for 8 weeks.The clinical effects,cognitive function,apoptosis factors,and incidence of adverse reactions were compared between the two groups.Results:The total effective rate was 93.33%in the observation group,higher than that of 73.33%in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of Montreal Cognitive Assessment(MoCA)and Mini-Mental State Examination(MMSE)between the two groups(P>0.05).After treatment,the scores of MoCA and MMSE in the observation group were higher than those before treatment and those in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of levels of Bax,Bcl-2 and cysteinyl aspartate specific proteinase-3(Caspase-3)between the two groups(P>0.05).After treatment,the levels of Bax and Caspase-3 in the observation group were lower than those before treatment and those in the control group(P<0.05),and Bcl-2 level was higher than that before treatment and that in the control group(P<0.05).There was no significant difference being found in the comparison of incidence of adverse reactions between the two groups(P>0.05).Conclusion:Qingxin Kaiqiao Prescription has a good effect in assisting treatment for mild-to-moderate Alzheimer disease,which can significantly improve cognitive function,and inhibit neural cells apoptosis with good safety.